I thought this new information was very important ...
Results of Eastern Cooperative Oncology Group Phase III clinical trial
E4A03, for multiple myeloma, showing significantly better overall
survival with lenalidomide (revlimid) plus low-dose dexamethasone therapy compared
to lenalidomide plus high-dose dexamethasone.
Full article:
http://www.eurekalert.org/pub_releases/2007-12/mc-mmc120607.
Regards,
Craig Persel